The licensed technology, with pending patent applications, has been developed by Vincent Falanga, chairman of the department of dermatology and skin surgery at Roger Williams Medical Center, Providence, Rhode Island.
Dr Falanga is also professor of dermatology and biochemistry at Boston University School of Medicine, a fellow of the American College of Physicians, and a past president of the Wound Healing Society, the scientific organization focused on this specialty.
Dr Falanga’s stem cell product under development, Primcel, is a mesenchymal stem cell product.
Robin Smith, CEO of NeoStem, said: “We are very pleased to sign this agreement with Dr Falanga. Acquisition of the exclusive worldwide rights to this wound healing technology will help advance NeoStem as a leader in the field of stem-cell tissue regeneration.”